Pricing Log in Create free account

Alzamend Neuro, Inc. (ALZN) vs Curis, Inc. (CRIS)

Alzamend Neuro, Inc. and Curis, Inc. are both Biotechnology companies. Alzamend Neuro, Inc. is the larger, with a market value of $7.5M against $5.7M — 1.3× the size. Across the 10 metrics below, Alzamend Neuro, Inc. leads on 5 and Curis, Inc. on 5.

Valuation

Metric ALZN CRIS Biotechnology median
P/E n/m n/m 10.26
P/S n/m 0.20 9.18
P/B 1.18 0.40 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA 0.05 0.29 0.65
EV/Sales n/m (0.27) 8.98
Earnings yield (150.33%) (1,634.48%) (34.89%)
Free cash flow yield (104.25%) (1,668.41%) (24.52%)

Profitability

Metric ALZN CRIS Biotechnology median
Gross margin 0.00% 99.52% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (163.23%) 455.35% (50.12%)
Return on assets (122.36%) (87.76%) (45.60%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric ALZN CRIS Biotechnology median
Revenue growth (TTM) — (13.43%) 6.26%
EPS growth (last fiscal year) 76.77% 91.57% 29.88%
Revenue growth, 5-year CAGR — (2.71%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ALZN CRIS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.01 0.49 4.89
Net debt to EBITDA 0.08 0.91 1.01

Dividend

Metric ALZN CRIS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ALZN CRIS Biotechnology median
Market cap 7.48m 5.67m 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack